Bliss Gvs Pharma Limited (IN:BLISSGVS)
:BLISSGVS
BLISSGVS Stock Chart & Stats
₹144.75
-₹6.85(-3.92%)
At close: 4:00 PM EST
₹144.75
-₹6.85(-3.92%)
Day’s Range― - ―
52-Week Range₹105.05 - ₹244.05
Previous CloseN/A
Volume571.01K
Average Volume (3M)104.36K
Market Cap
₹24.79B
Enterprise Value₹23.41B
Total Cash (Recent Filing)₹2.01B
Total Debt (Recent Filing)₹524.91M
Price to Earnings (P/E)18.6
Beta1.40
Next Earnings
May 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.28%
Share Statistics
EPS (TTM)2.20
Shares Outstanding105,788,970
10 Day Avg. Volume77,644
30 Day Avg. Volume104,358
Financial Highlights & Ratios
PEG Ratio1.37
Price to Book (P/B)1.20
Price to Sales (P/S)1.56
P/FCF Ratio42.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Balance SheetThe company maintains a high equity ratio and low leverage, per the balance sheet summary. This structural capital strength supports investment, withstands demand shocks, and preserves strategic optionality for R&D, regulatory compliance costs, or tender-backed working capital over the next 2–6 months.
Improving Profitability And MarginsReported increases in gross, net, EBIT and EBITDA margins reflect sustained operational improvements and cost management. Better margins enhance cash generation capacity and resilience to pricing pressure in generics, supporting durable earnings quality over the medium term.
Diversified Pharma Revenue StreamsBliss GVS's mix of domestic finished-dose sales, export orders and contract manufacturing, plus a focused contraceptive/reproductive-health franchise, provides multiple durable revenue channels. This breadth mitigates single-market risk and supports repeat institutional and tender business continuity.
Bears Say
Mixed Cash Flow PerformanceVariability in free cash flow growth reduces predictability of internal funding for capex, working capital and potential dividends. Even with healthy operating cash conversion, inconsistent FCF complicates strategic planning and may constrain reinvestment or buffer against cyclical demand shifts.
Very Low Dividend Income SupportA very low dividend yield offers minimal shareholder income and reduces the stock’s attractiveness to income-focused investors. Over a multi-month horizon this limits a stable cash-return channel, forcing reliance on earnings growth rather than dividend distribution for shareholder value.
Modest Revenue Growth With EBITDA InconsistencyRevenue growth near 7% is positive but modest for scaling pharmaceutical operations; combined with noted inconsistency in EBITDA, this may constrain margin expansion and reinvestment capacity. Sustained, predictable top-line growth is needed to lock in operating leverage and fund strategic initiatives.
Bliss Gvs Pharma Limited News
BLISSGVS FAQ
What was Bliss Gvs Pharma Limited’s price range in the past 12 months?
Bliss Gvs Pharma Limited lowest stock price was ₹105.05 and its highest was ₹244.05 in the past 12 months.
What is Bliss Gvs Pharma Limited’s market cap?
Bliss Gvs Pharma Limited’s market cap is ₹24.79B.
When is Bliss Gvs Pharma Limited’s upcoming earnings report date?
Bliss Gvs Pharma Limited’s upcoming earnings report date is May 13, 2026 which is in 37 days.
How were Bliss Gvs Pharma Limited’s earnings last quarter?
Bliss Gvs Pharma Limited released its earnings results on Feb 10, 2026. The company reported ₹2.2 earnings per share for the quarter, beating the consensus estimate of N/A by ₹2.2.
Is Bliss Gvs Pharma Limited overvalued?
According to Wall Street analysts Bliss Gvs Pharma Limited’s price is currently Overvalued.
Does Bliss Gvs Pharma Limited pay dividends?
Bliss Gvs Pharma Limited pays a Annually dividend of ₹0.5 which represents an annual dividend yield of 0.28%. See more information on Bliss Gvs Pharma Limited dividends here
What is Bliss Gvs Pharma Limited’s EPS estimate?
Bliss Gvs Pharma Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bliss Gvs Pharma Limited have?
Bliss Gvs Pharma Limited has 105,788,970 shares outstanding.
What happened to Bliss Gvs Pharma Limited’s price movement after its last earnings report?
Bliss Gvs Pharma Limited reported an EPS of ₹2.2 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.791%.
Which hedge fund is a major shareholder of Bliss Gvs Pharma Limited?
Currently, no hedge funds are holding shares in IN:BLISSGVS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bliss Gvs Pharma Limited
Bliss GVS Pharma Limited develops, manufactures, and markets pharmaceutical formulations in India. It offers pharma products, including capsules, creams/gels/ointments, dry powder for injections and oral suspensions, effervescent tablets, eye/ear drops, injections, liquid preparations, lotions, lozenges, nasal solutions, oral solids, parenterals, pessaries, sachets, soft gelatin capsules, suppositories, suspensions, syrups, tablets, topical preparations, and transdermal patches. The company also provides other healthcare products, such as balms, creams, lotions, lozenges, nasal inhalers, over the counter products, petroleum jellies, powders, roll-ons, shampoos, soaps, solutions, sprays, syrups, and vaginal washes. In addition, it offers therapeutic products consisting of anti-bacterial, anti-dandruff shampoo, amino acid preparation, iron tonic, antitussive, appetite stimulant, anti-allergic, body supplement, anti-biotic, anti-diabetic, anti-diarrheal, anti-emetic, anti-fungal, anti-haemorrhoidal, anti-helmintic, anti-infective, anti-inflammatory, anti-malarial, anti-microbial, anti-migraine, anti-oxidant, anti-protozoal, ear wax solvent, anti-pyretic, anti-septic, anti-spasmodic, anti-ulcer, and anti-ulcerant; and analgesic, oral rehydration, antacid, anxiolytic, appetizer, cough syrup, erectile dysfunction, haematinic, hand sanitizer, health supplement, insecticide, laryngitis, pharyngitis, laxative, lubricant, mosquito repellant, nasal decongestant, nutritional supplement, moisturizer, prickly heat powder, skin lightening lotion, vaginal contraceptive, vaginal hygiene, and vitamin supplements, as well as medicated, complexion, moisturizing, and total protection soaps. The company also exports its products. Bliss GVS Pharma Limited was incorporated in 1984 and is based in Mumbai, India.
Technical Analysis
Bajaj Healthcare Ltd
―
Hester Biosciences Limited
―
Jagsonpal Pharmaceuticals Ltd.
―
Syncom Formulation (India) Ltd.
―
Windlas Biotech Ltd.
―